CN104039245A - 可膨胀的闭塞装置和方法 - Google Patents
可膨胀的闭塞装置和方法 Download PDFInfo
- Publication number
- CN104039245A CN104039245A CN201280048878.1A CN201280048878A CN104039245A CN 104039245 A CN104039245 A CN 104039245A CN 201280048878 A CN201280048878 A CN 201280048878A CN 104039245 A CN104039245 A CN 104039245A
- Authority
- CN
- China
- Prior art keywords
- screen work
- layer
- axle
- rack
- blocking element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000031018 biological processes and functions Effects 0.000 claims abstract description 7
- 230000000903 blocking effect Effects 0.000 claims description 99
- 239000000463 material Substances 0.000 claims description 70
- 210000001519 tissue Anatomy 0.000 claims description 29
- 230000008961 swelling Effects 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 230000008602 contraction Effects 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 5
- 210000005003 heart tissue Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005253 cladding Methods 0.000 claims 3
- 238000009954 braiding Methods 0.000 abstract description 15
- 208000025339 heart septal defect Diseases 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 125
- 239000004744 fabric Substances 0.000 description 25
- 238000005516 engineering process Methods 0.000 description 19
- 230000017531 blood circulation Effects 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 208000028831 congenital heart disease Diseases 0.000 description 7
- 210000005246 left atrium Anatomy 0.000 description 7
- 210000005241 right ventricle Anatomy 0.000 description 7
- 208000035478 Interatrial communication Diseases 0.000 description 6
- 208000008883 Patent Foramen Ovale Diseases 0.000 description 6
- 208000013914 atrial heart septal defect Diseases 0.000 description 6
- 206010003664 atrial septal defect Diseases 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 229910001000 nickel titanium Inorganic materials 0.000 description 6
- 210000005245 right atrium Anatomy 0.000 description 6
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 5
- -1 for example Polymers 0.000 description 5
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 5
- 201000003130 ventricular septal defect Diseases 0.000 description 5
- 208000005189 Embolism Diseases 0.000 description 4
- 208000001435 Thromboembolism Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000007769 metal material Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 239000010937 tungsten Substances 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 208000003278 patent ductus arteriosus Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 2
- 229960003856 argatroban Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 238000009998 heat setting Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000004971 interatrial septum Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 229950007952 vapiprost Drugs 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 229960001522 ximelagatran Drugs 0.000 description 2
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- BISKEOIROPAOGY-RXQQAGQTSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2r)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@@H](NC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C=O)C1=CC=CC=C1 BISKEOIROPAOGY-RXQQAGQTSA-N 0.000 description 1
- PWINFPFVCZSLBF-RTWAWAEBSA-N (3s)-4-[[(2r)-1-amino-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-[[2-[ethyl(4-piperidin-4-ylbutanoyl)amino]acetyl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CN(CC)C(=O)CCCC1CCNCC1)C(N)=O)C1CCCCC1 PWINFPFVCZSLBF-RTWAWAEBSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000005320 Coleus barbatus Nutrition 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000131459 Plectranthus barbatus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001227561 Valgus Species 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 108010078659 efegatran Proteins 0.000 description 1
- 229950009814 efegatran Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- ZHCINJQZDFCSEL-CYBMUJFWSA-N ethyl (3s)-3-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]pent-4-ynoate Chemical compound CCOC(=O)C[C@@H](C#C)NC(=O)CCC(=O)NC1=CC=C(C(N)=N)C=C1 ZHCINJQZDFCSEL-CYBMUJFWSA-N 0.000 description 1
- VJDOPFARMOLELX-ZDUSSCGKSA-N ethyl 3-[[(3s)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate Chemical compound O=C1[C@@H](NC(=O)NCCC(=O)OCC)CCN1C1=CC=C(C(N)=N)C=C1 VJDOPFARMOLELX-ZDUSSCGKSA-N 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 210000004491 foramen ovale Anatomy 0.000 description 1
- 229950008851 fradafiban Drugs 0.000 description 1
- IKZACQMAVUIGPY-HOTGVXAUSA-N fradafiban Chemical compound C1=CC(C(=N)N)=CC=C1C(C=C1)=CC=C1OC[C@H]1NC(=O)[C@H](CC(O)=O)C1 IKZACQMAVUIGPY-HOTGVXAUSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 108010073077 klerval Proteins 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229950003178 lamifiban Drugs 0.000 description 1
- FPKOGTAFKSLZLD-FQEVSTJZSA-N lamifiban Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N[C@H](C(=O)N1CCC(CC1)OCC(O)=O)CC1=CC=C(O)C=C1 FPKOGTAFKSLZLD-FQEVSTJZSA-N 0.000 description 1
- PGCFXITVMNNKON-ROUUACIJSA-N lefradafiban Chemical compound N1C(=O)[C@H](CC(=O)OC)C[C@H]1COC1=CC=C(C=2C=CC(=CC=2)C(=N)NC(=O)OC)C=C1 PGCFXITVMNNKON-ROUUACIJSA-N 0.000 description 1
- 229950011635 lefradafiban Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 229950010501 lotrafiban Drugs 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229950002383 orbofiban Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 229950004893 xemilofiban Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12122—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder within the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00592—Elastic or resilient implements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00606—Implements H-shaped in cross-section, i.e. with occluders on both sides of the opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00619—Locking means for locking the implement in expanded state
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00623—Introducing or retrieving devices therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00632—Occluding a cavity, i.e. closing a blind opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00853—Material properties low friction, hydrophobic and corrosion-resistant fluorocarbon resin coating (ptf, ptfe, polytetrafluoroethylene)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00867—Material properties shape memory effect
- A61B2017/00871—Material properties shape memory effect polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Surgical Instruments (AREA)
- Prostheses (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525680P | 2011-08-19 | 2011-08-19 | |
| US61/525,680 | 2011-08-19 | ||
| US201261636392P | 2012-04-20 | 2012-04-20 | |
| US61/636,392 | 2012-04-20 | ||
| PCT/US2012/051502 WO2013028579A1 (en) | 2011-08-19 | 2012-08-17 | Expandable occlusion device and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104039245A true CN104039245A (zh) | 2014-09-10 |
Family
ID=47746794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280048878.1A Pending CN104039245A (zh) | 2011-08-19 | 2012-08-17 | 可膨胀的闭塞装置和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140343602A1 (enExample) |
| EP (1) | EP2744423A4 (enExample) |
| JP (1) | JP6240604B2 (enExample) |
| CN (1) | CN104039245A (enExample) |
| BR (1) | BR112014003895A2 (enExample) |
| WO (1) | WO2013028579A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106691363A (zh) * | 2012-02-07 | 2017-05-24 | 赫莱达雅公司 | 血液动力学辅助设备 |
| CN109875642A (zh) * | 2019-03-11 | 2019-06-14 | 恩脉（上海）医疗科技有限公司 | 一种取栓装置 |
| WO2019144870A1 (zh) * | 2018-01-25 | 2019-08-01 | 杭州唯强医疗科技有限公司 | 主动脉夹层破口封堵装置 |
| US11389638B2 (en) | 2012-02-07 | 2022-07-19 | Hridaya, Inc. | Hemodynamic assist device |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9498604B2 (en) | 1997-11-12 | 2016-11-22 | Genesis Technologies Llc | Medical device and method |
| US9861346B2 (en) | 2003-07-14 | 2018-01-09 | W. L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with linearly elongating petals |
| WO2008124603A1 (en) | 2007-04-05 | 2008-10-16 | Nmt Medical, Inc. | Septal closure device with centering mechanism |
| US20130165967A1 (en) | 2008-03-07 | 2013-06-27 | W.L. Gore & Associates, Inc. | Heart occlusion devices |
| US8956389B2 (en) | 2009-06-22 | 2015-02-17 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
| US20120029556A1 (en) | 2009-06-22 | 2012-02-02 | Masters Steven J | Sealing device and delivery system |
| WO2018217878A1 (en) * | 2010-04-29 | 2018-11-29 | Muffin Incorporated | Closing device for tissue openings |
| US20180049731A1 (en) * | 2010-04-29 | 2018-02-22 | Muffin Incorporated | Closing device for tissue openings |
| US10568628B2 (en) * | 2017-05-23 | 2020-02-25 | Muffin Incorporated | Closing device for tissue openings |
| US10335577B2 (en) | 2010-05-19 | 2019-07-02 | Nfinium Vascular Technologies, Llc | Augmented delivery catheter and method |
| US9561094B2 (en) | 2010-07-23 | 2017-02-07 | Nfinium Vascular Technologies, Llc | Devices and methods for treating venous diseases |
| CA2829097C (en) | 2011-03-08 | 2016-01-05 | W. L. Gore & Associates, Inc. | Medical device for use with a stoma |
| FR2976992A1 (fr) * | 2011-06-22 | 2012-12-28 | Conseil Et Tech | Dispositif de ressort |
| US9770232B2 (en) | 2011-08-12 | 2017-09-26 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
| IN2014DN05897A (enExample) * | 2012-01-06 | 2015-06-05 | Inceptus Medical LLC | |
| US10828019B2 (en) * | 2013-01-18 | 2020-11-10 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
| US20150018860A1 (en) | 2013-07-12 | 2015-01-15 | Inceptus Medical, Llc | Methods and apparatus for treating small vessel thromboembolisms |
| EP3136986B1 (en) | 2014-04-30 | 2019-04-17 | Cerus Endovascular Limited | Occlusion device |
| US11439396B2 (en) | 2014-05-02 | 2022-09-13 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
| US9993251B2 (en) | 2014-05-02 | 2018-06-12 | W. L. Gore & Associates, Inc. | Anastomosis devices |
| US11712230B2 (en) | 2014-05-02 | 2023-08-01 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
| EP3151904A4 (en) | 2014-06-04 | 2018-02-14 | Nfinium Vascular Technologies, LLC | Low radial force vascular device and method of occlusion |
| US9808230B2 (en) | 2014-06-06 | 2017-11-07 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
| CN106794015B (zh) * | 2014-07-18 | 2020-10-27 | 伊西康公司 | 用于减小肺容积的通过栓系实现的机械回缩 |
| EP3169250B1 (en) | 2014-07-18 | 2019-08-28 | Ethicon, Inc. | Devices for controlling the size of emphysematous bullae |
| CN107530523B (zh) | 2015-02-25 | 2021-03-19 | 盖乐西医疗公司 | 治疗动脉瘤的系统 |
| US20180103956A1 (en) * | 2015-04-27 | 2018-04-19 | Gunze Limited | Medical material |
| EP4403129A3 (en) | 2015-12-07 | 2024-09-18 | Stryker Ireland Technology Ltd. | Occlusion device |
| CN105496603B (zh) * | 2015-12-30 | 2018-11-06 | 先健科技(深圳)有限公司 | 管腔支架 |
| EP3426181B1 (en) | 2016-03-11 | 2020-10-21 | Cerus Endovascular Limited | Occlusion device |
| CN109069160B (zh) * | 2016-03-17 | 2022-05-17 | S·珍耶那曼 | 封堵解剖结构 |
| US12232737B2 (en) | 2016-03-17 | 2025-02-25 | Eclipse Medical Limited | Occluding anatomical structures |
| US20180049859A1 (en) * | 2016-08-16 | 2018-02-22 | Spartan Micro, Inc. | Intravascular flow diversion devices |
| EP3526379B1 (en) | 2016-10-14 | 2021-08-11 | Inceptus Medical, LLC | Braiding machine and methods of use |
| US11395644B2 (en) | 2017-02-13 | 2022-07-26 | Gulf Medical Technologies | Sinus venosus atrial septal defect treatment device |
| US10531867B2 (en) | 2017-02-13 | 2020-01-14 | Muath Alanbaei | Sinus venosus atrial septal defect treatment device |
| JP7296317B2 (ja) | 2017-02-24 | 2023-06-22 | インセプタス メディカル リミテッド ライアビリティ カンパニー | 血管閉塞装置および方法 |
| CN108685599B (zh) * | 2017-04-06 | 2020-07-17 | 先健科技(深圳)有限公司 | 封堵器及封堵装置 |
| US11724075B2 (en) | 2017-04-18 | 2023-08-15 | W. L. Gore & Associates, Inc. | Deployment constraining sheath that enables staged deployment by device section |
| JP7134229B2 (ja) | 2017-07-06 | 2022-09-09 | ラグビア バスデ， | 組織把持デバイスおよび関連方法 |
| WO2019038293A1 (en) | 2017-08-21 | 2019-02-28 | Cerus Endovascular Limited | OCCLUSION DEVICE |
| CN111542657B (zh) | 2017-10-14 | 2022-08-16 | 因赛普特斯医学有限责任公司 | 编织机及其使用方法 |
| US11185335B2 (en) | 2018-01-19 | 2021-11-30 | Galaxy Therapeutics Inc. | System for and method of treating aneurysms |
| US11272940B2 (en) * | 2018-03-16 | 2022-03-15 | Microvention, Inc. | Devices for mitigating vessel leakage |
| WO2019199640A1 (en) | 2018-04-10 | 2019-10-17 | Medstar Health | Embolization scaffold devices |
| CN111150433B (zh) * | 2018-11-08 | 2024-12-31 | 先健科技(深圳)有限公司 | 封堵器 |
| JP7279918B2 (ja) * | 2018-11-15 | 2023-05-23 | グンゼ株式会社 | 医療用材料 |
| EP3911276A4 (en) * | 2019-01-14 | 2022-09-28 | Valfix Medical Ltd. | ANCHORS AND LOCKS FOR PERCUTANEOUS VALVE IMPLANTS |
| WO2020221233A1 (zh) * | 2019-04-29 | 2020-11-05 | 上海锦葵医疗器械股份有限公司 | 两端无外突点结构的封堵器 |
| US12102327B2 (en) | 2019-05-25 | 2024-10-01 | Galaxy Therapeutics, Inc. | Systems and methods for treating aneurysms |
| US11058431B2 (en) | 2019-05-25 | 2021-07-13 | Galaxy Therapeutics, Inc. | Systems and methods for treating aneurysms |
| US11679458B2 (en) * | 2019-11-04 | 2023-06-20 | Covidien Lp | Devices, systems, and methods for treating aneurysms |
| CA3168856A1 (en) * | 2020-01-24 | 2021-07-29 | PatchClamp Medtech, Inc. | Tissue repair and sealing devices having a detachable graft and clasp assembly and methods for the use thereof |
| US20210236102A1 (en) * | 2020-02-03 | 2021-08-05 | St. Jude Medical, Cardiology Division, Inc. | Occluder locking mechanisms |
| US11406404B2 (en) | 2020-02-20 | 2022-08-09 | Cerus Endovascular Limited | Clot removal distal protection methods |
| CN112690855B (zh) * | 2020-12-31 | 2023-02-03 | 先健科技(深圳)有限公司 | 封堵器及封堵装置 |
| EP4284263A4 (en) | 2021-01-27 | 2024-06-26 | Galaxy Therapeutics, Inc. | SYSTEMS AND METHODS FOR TREATING ANEURYSMS |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2525962Y (zh) * | 2002-01-25 | 2002-12-18 | 同济大学 | 心脏间隔缺损封闭器 |
| US20090275974A1 (en) * | 2008-05-02 | 2009-11-05 | Philippe Marchand | Filamentary devices for treatment of vascular defects |
| CN101687088A (zh) * | 2007-06-21 | 2010-03-31 | Aga医药有限公司 | 阻塞血管缺损的多层编织结构 |
| US20110152993A1 (en) * | 2009-11-05 | 2011-06-23 | Sequent Medical Inc. | Multiple layer filamentary devices or treatment of vascular defects |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1221307B1 (en) * | 1994-07-08 | 2010-02-17 | ev3 Inc. | System for performing an intravascular procedure |
| US6152144A (en) * | 1998-11-06 | 2000-11-28 | Appriva Medical, Inc. | Method and device for left atrial appendage occlusion |
| US20030057156A1 (en) * | 2001-03-08 | 2003-03-27 | Dean Peterson | Atrial filter implants |
| US9039724B2 (en) * | 2004-03-19 | 2015-05-26 | Aga Medical Corporation | Device for occluding vascular defects |
| ZA200604868B (en) * | 2004-04-08 | 2008-01-30 | Aga Medical Corp | Flange occlusion devices and methods |
| CN101049266B (zh) * | 2006-04-03 | 2010-11-17 | 孟坚 | 医疗用闭塞器械及其制造方法 |
| US8597341B2 (en) * | 2006-03-06 | 2013-12-03 | David Elmaleh | Intravascular device with netting system |
| US8361138B2 (en) * | 2007-07-25 | 2013-01-29 | Aga Medical Corporation | Braided occlusion device having repeating expanded volume segments separated by articulation segments |
| US20090082803A1 (en) * | 2007-09-26 | 2009-03-26 | Aga Medical Corporation | Braided vascular devices having no end clamps |
| US20090171386A1 (en) * | 2007-12-28 | 2009-07-02 | Aga Medical Corporation | Percutaneous catheter directed intravascular occlusion devices |
| WO2010006061A2 (en) | 2008-07-11 | 2010-01-14 | Mayo Foundation For Medical Education And Research | Left atrial appendage occlusion devices |
-
2012
- 2012-08-17 US US14/239,129 patent/US20140343602A1/en not_active Abandoned
- 2012-08-17 EP EP12825306.9A patent/EP2744423A4/en not_active Withdrawn
- 2012-08-17 JP JP2014527211A patent/JP6240604B2/ja active Active
- 2012-08-17 BR BR112014003895A patent/BR112014003895A2/pt not_active IP Right Cessation
- 2012-08-17 WO PCT/US2012/051502 patent/WO2013028579A1/en not_active Ceased
- 2012-08-17 CN CN201280048878.1A patent/CN104039245A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2525962Y (zh) * | 2002-01-25 | 2002-12-18 | 同济大学 | 心脏间隔缺损封闭器 |
| CN101687088A (zh) * | 2007-06-21 | 2010-03-31 | Aga医药有限公司 | 阻塞血管缺损的多层编织结构 |
| US20090275974A1 (en) * | 2008-05-02 | 2009-11-05 | Philippe Marchand | Filamentary devices for treatment of vascular defects |
| US20110152993A1 (en) * | 2009-11-05 | 2011-06-23 | Sequent Medical Inc. | Multiple layer filamentary devices or treatment of vascular defects |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106691363A (zh) * | 2012-02-07 | 2017-05-24 | 赫莱达雅公司 | 血液动力学辅助设备 |
| CN106691363B (zh) * | 2012-02-07 | 2019-05-03 | 赫莱达雅公司 | 血液动力学辅助设备 |
| US11389638B2 (en) | 2012-02-07 | 2022-07-19 | Hridaya, Inc. | Hemodynamic assist device |
| US12042410B2 (en) | 2012-02-07 | 2024-07-23 | Sanjaya Khanal | Hemodynamic assist device |
| WO2019144870A1 (zh) * | 2018-01-25 | 2019-08-01 | 杭州唯强医疗科技有限公司 | 主动脉夹层破口封堵装置 |
| CN109875642A (zh) * | 2019-03-11 | 2019-06-14 | 恩脉（上海）医疗科技有限公司 | 一种取栓装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2744423A4 (en) | 2015-06-24 |
| JP2014529441A (ja) | 2014-11-13 |
| BR112014003895A2 (pt) | 2017-03-21 |
| WO2013028579A1 (en) | 2013-02-28 |
| EP2744423A1 (en) | 2014-06-25 |
| US20140343602A1 (en) | 2014-11-20 |
| JP6240604B2 (ja) | 2017-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104039245A (zh) | 可膨胀的闭塞装置和方法 | |
| US20240065840A1 (en) | Flow regulating device in the heart | |
| US9375209B2 (en) | Medical implantable occlusion device, and method for implantation thereof | |
| US10631839B2 (en) | Implantable device | |
| EP3563773B1 (en) | Occluder and method for sewing an occluder | |
| EP2340077B1 (en) | Device for occluding vascular defects | |
| EP3398534B1 (en) | Occluder | |
| AU2013304936A1 (en) | Implant | |
| EP2596754A1 (en) | Medical implant and manufacturing method thereof | |
| US20150066077A1 (en) | Device For Occluding An Opening In A Body And Associated Methods | |
| EP2387950A1 (en) | Medical implant and manufacturing method thereof | |
| BRPI0720347B1 (pt) | Dispositivo implantável | |
| US20210059684A1 (en) | Erosion mitigating occluder | |
| EP2967579A1 (en) | Multilayered expandable braided devices and methods of use | |
| CN107374688A (zh) | 一种管腔内封堵装置 | |
| WO2018145535A1 (zh) | 封堵器 | |
| US20260053483A1 (en) | Occluder including external skirt | |
| RU128101U1 (ru) | Окклюдер | |
| US20250345065A1 (en) | Left Atrial Appendage Occluder with Pulmonary Ridge Disc Coverage | |
| WO2025007807A1 (zh) | 血管支架 | |
| CN118806364A (zh) | 封堵器 | |
| HK1159006B (en) | Device for occluding vascular defects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140910 |